Girentuximab

Tax included
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).
MedChemExpress 
HY-P99023

Data sheet

Size
Multiple sizes
Reactivity
Carbonic Anhydrase
Application
Cancer-programmed cell death
CAS
916138-87-9